Protagonist Therapeutics Reports Granting of Inducement Awards
Rhea-AI Summary
Protagonist Therapeutics (Nasdaq:PTGX) granted equity inducement awards to three new employees on June 15, 2026, under its Amended and Restated Inducement Plan.
The grants total 14,800 stock options at a $112.46 exercise price and 3,900 RSUs, with four-year vesting schedules, approved under Nasdaq Rule 5635(c)(4).
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PTGX
On the day this news was published, PTGX gained 0.72%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Clinical data presentations | Positive | -4.7% | Phase 3 VERIFY and long-term rusfertide data slated for EHA Congress. |
| May 28 | Conference participation | Neutral | -1.8% | CEO scheduled for fireside chats at two June healthcare conferences. |
| May 05 | Earnings and update | Positive | +4.8% | Q1 2026 results with ICOTYDE approval and strong rusfertide economics. |
| Apr 28 | Collaboration opt-out | Positive | +2.7% | Rusfertide U.S. opt-out under Takeda deal, unlocking major milestone potential. |
| Apr 16 | Inducement awards | Neutral | +2.2% | Stock options and RSUs granted to new hires under inducement plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw price moves that did not clearly track headline positivity, with both positive corporate updates and routine items followed by mixed reactions.
Over the past few months, PTGX has reported several important milestones. On April 28, 2026, it exercised its U.S. opt-out right under the Takeda collaboration for rusfertide, with shares reacting positively. Q1 2026 results on May 5, 2026 highlighted FDA approval of ICOTYDE, substantial milestone economics, and a cash position of $620.3 million, again with a positive move. In contrast, presentation-focused and conference-participation updates on May 28 and June 1, 2026 were followed by declines. A prior inducement-award announcement on April 16, 2026 coincided with a modest gain.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration dated 2025-08-06, expiring on 2028-08-06. It shows 0 recorded usages to date in the provided data, indicating no takedowns have been logged from this shelf.
Key Terms
restricted stock units (rsus) financial
nasdaq global market regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
The new employees received, in the aggregate, options to purchase 14,800 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,900 shares of Protagonist Therapeutics common stock. The exercise price of the options is
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire